Showing results (311-320 of 331) with videos related to
Sort By:
Pageof 34
Diabetes & Metabolism Journal|August 31, 2013
Diabetes epidemics in Korea: reappraise nationwide survey of diabetes "diabetes in Korea 2007", Ie Byung Park, Jaiyong Kim, et al.The Korean Journal of Internal Medicine|May 12, 2017
Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter studyHae Jin Kim, Seung Jin Han, Dae Jung Kim, et al.Oncology Reports|September 6, 2005
Three novel VHL germline mutations in Korean patients with von Hippel-Lindau disease and pheochromocytomasHio Chung Kang, Il-Jin Kim, Jae-Hyun Park, et al.Journal of Research in Medical Sciences : the Official Journal of Isfahan University of Medical Sciences|April 17, 2019
The association of diabetes duration and glycemic control with depression in elderly men with type 2 diabetes mellitusHae Jin Kim, So-Yeon An, Seung Jin Han, et al.The Lancet. Diabetes & Endocrinology|November 14, 2024
Trends in the incidence of young-adult-onset diabetes by diabetes type: a multi-national population-based study from an international diabetes consortiumDianna J Magliano, Lei Chen, Jedidiah I Morton, et al.The Lancet. Diabetes & Endocrinology|June 20, 2020
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort studyShun Kohsaka, Carolyn S P Lam, Dae Jung Kim, et al.Respiration; International Review of Thoracic Diseases|August 18, 2015
Independent risk factors for mortality in patients with chronic obstructive pulmonary disease who undergo comprehensive cardiac evaluationsYoung-Hwan Ahn, Keu Sung Lee, Joo Hun Park, et al.Diabetes & Metabolism Journal|August 24, 2019
2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in KoreaMee Kyoung Kim, Seung Hyun Ko, Bo Yeon Kim, et al.Cardiovascular Diabetology|August 1, 2021
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL dataKamlesh Khunti, Mikhail Kosiborod, Dae Jung Kim, et al.Cardiovascular Diabetology|August 31, 2023
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and AsiaDorte Vistisen, Bendix Carstensen, Patorno Elisabetta, et al.Pageof 34